The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...

A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...

The gene therapy world is in turmoil, but Arbor, armed with more than a billion dollars in partnerships and raises, is going forward.

Researchers are using gene editing techniques to introduce beneficial traits like polled and disease resistance, as well as ...

Digital_Genome_Market1 The digital genome market is dominated by America owing increasing prevalence of chronic diseases like cancer and di ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Researchers at Duke University and North Carolina State University have discovered a handful of new CRISPR-Cas systems that ...

Shortly after this publication, Bogdanove struck up a collaboration with Daniel Voytas, a plant geneticist at the University ...

The germany DNA polymerase market is set for significant expansion, with projections indicating a rise from USD 20.7 million in 2025 to USD 40.0 million by 2035, driven by a 6.8% CAGR. As a leading ...

The Global Synthetic Biology Market is estimated to be valued at USD 13.83 billion in 2023 and is projected to expand at a robust Compound Annual Growth Rate (CAGR) of 17.30% over the forecast period ...